

# C9 deficiency

## GENERAL INFORMATION

### Description:

C9 is a glycoprotein which has sequence homology to C8alpha, C8beta, C6, and perforin. C9 is produced by hepatocytes, it is cytokine inducible and behaves as an acute phase reactant. Patients with C9 deficiency have reduced levels of C9 in their serum. They possess some serum hemolytic and bactericidal activity but less than in normal serum.

### Alternative names:

- Complement component 9 deficiency

### Classification:

- Defects of the classical complement cascade proteins

### Inheritance:

Autosomal recessive

### OMIM:

- +120940 Complement component 9; C9

### Cross references:

#### Phenotype related immunodeficiencies:

- IDR factfile for C5 deficiency
- IDR factfile for C6 deficiency
- IDR factfile for C7 deficiency
- IDR factfile for C8 alpha-polypeptide deficiency
- IDR factfile for C8 beta-polypeptide deficiency
- IDR factfile for C8 gamma-polypeptide deficiency

### Incidence:

Incidence is not known.

## CLINICAL INFORMATION

### Description:

Patients with C9 deficiency are often asymptomatic but some present systemic meningococcal infections. In Japan C9 deficiency is relatively common. Patients with C9 deficiency have the ability to kill *Neisseria* but at a slower rate.

### Diagnosis:

#### Diagnostic laboratories:

#### Clinical:

- Complement deficiency, eMedicine

#### Therapeutic options:

- Fresh frozen plasma is used for emergent replacement of complement components. Supportive therapy is used for complement deficiencies. Prophylactic antibiotics for the infections. Specific treatment of autoimmune disease is followed.
- Complement deficiency, eMedicine
- Complement deficiency, eMedicine

#### Research programs, clinical trials:

- European Initiative for Primary Immunodeficiencies
- Molecular and Clinical Studies of Primary Immunodeficiency diseases, ClinicalTrials.gov
- Swegene Project

## GENE INFORMATION

### Names:

**HUGO name:** C9

**Alias(es):** complement component 9,  
Complement component C9 precursor

### Localization:

#### Reference sequences:

**DNA:** C9\_DNA (C9base) , **cDNA:** X02176 (EMBL) , **Protein:** P02748 (SWISSPROT)  
Other Sequences

#### Chromosomal Location:

5p13

#### Maps:

C9 (Map View)

### Variations / Mutations:

- C9base; Mutation registry for C9 deficiency.

### Other gene-based resources:

Ensembl: ENSG00000113600, GENATLAS: C9,  
GeneCard: C9, UniGene: 1290, Entrez Gene:  
735, euGenes: 735, GDB: 119738

## PROTEIN INFORMATION

### Description:

#### Protein function:

C9 is the final component of the complement system to be added in the assembly of the membrane attack complex. It is able to enter lipid bilayers, forming transmembrane channels.

#### Post-translational modification:

Thrombin cleaves factor C9 to produce C9a and C9b.

### Other features:

#### Other related resources:

PIR: C9HU, InterPro: IPR006210; EGF-like, InterPro: IPR002172; LDL\_recept\_A, InterPro: IPR001862; MAC\_perforin, InterPro: IPR000884; TSP1, Pfam: PF00057; ldl\_recept\_a, Pfam: PF00090; tsp\_1, Pfam: PF01823; MACPF, SMART: SM00192; LDLa, SMART: SM00457; MACPF, SMART: SM00209; TSP1, PROSITE: PS00022; EGF\_1, PROSITE: PS01186; EGF\_2, PROSITE: PS01209; LDLRA\_1, PROSITE: PS50068; LDLRA\_2, PROSITE: PS00279; MAC\_PERFORIN, PROSITE: PS50092; TSP1

### Expression pattern for human:

Tissue	Exp. (%)	Clones
liver	34.57	34:26031
corresponding non cancerous liver tissue	26.64	14:13909
hepatocellular carcinoma	22.33	12:14226
placenta human 8 week	13.12	2:4035
muscle (skeletal)	2.77	1:9571
pool, lung+testis+b-cell	0.48	1:55714
brain	0.10	1:274929

## OTHER RESOURCES

### Societies:

#### General:

- International Patient Organization for Primary Immunodeficiencies
- Immune Deficiency Foundation
- NIH/National Institute of Allergy and Infectious Diseases
- European Society for Immunodeficiencies